(Reuters) -iTeos Therapeutics and partner GSK said on Tuesday they have terminated development of their experimental lung cancer therapy after its failure to significantly improve progression-free survival in two mid-stage trials.
The therapy, belrestotug, which was being tested in combination with GSK’s dostarlimab for treating non-small cell lung cancer, did not demonstrate sufficient efficacy, leading to the termination of the collaboration, the companies said.
“We are truly disappointed by the results,” said iTeos Chief Executive Officer Michel Detheux.
The companies will now cease enrolling new patients in the ongoing late-stage lung cancer trial.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Anil D’Silva and Shinjini Ganguli)
Comments